Bristol-Myers upgraded at Leerink
Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from boutiques ...
Leerink downgraded 908 Devices (MASS) to Market Perform from Outperform with a price target of $4, down from $12. Though the firm still sees ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Leerink Partnrs cut their FY2024 EPS estimates for Celldex ...
Leerink notes that Syndax (SNDX) has disclosed topline pivotal data for menin-MLL inhibitor revumenib in NPM1m acute leukemia, which the firm ...
Leerink Partners CIO Jeff Gerson on how the firm realigned its technology strategies and services after it demerged from SVB ...
Leerink Partners has recently resumed MannKind Corp (MNKD) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on June 13, 2024, Rodman & Renshaw had ...
Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a ...
Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease ...
In a report released on November 11, Roanna Ruiz from Leerink Partners maintained a Buy rating on ARS Pharmaceuticals (SPRY – Research Report). The company’s shares closed yesterday at $16.61.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback